Abstract
Complement is one of primary defense mechanisms against intravascular microorganisms and could play a role in the immune response to malignancy and hence its clinical behavior. We evaluated if the sole coding polymorphism of C1qA associates with outcome in patients with breast carcinoma. Genotyping for C1qA[276A/G] was performed in 63 breast cancer subjects with localized tumor and compared with that in 38 breast cancer subjects with metastasis. Established risk factors for clinical outcome were considered and evaluated in multivariable analysis. Breast cancer subjects with heterozygous or homozygous C1qA[276G] genotype had a higher rate of metastasis than subjects with the homozygous C1qA[276A] genotype [hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.1–4.1]. This association was stronger when only metastatic sites associated with hematogenous spread, i.e., to the bone, liver, and brain, were considered (HR 3.5, 95% CI 1.4–5.6) and remained statistically significant after adjustment for the number of positive lymph nodes, estrogen receptor status, and progesterone receptor status. There was no statistical difference in the C1qA[276A/G] allelic distribution between all subjects with breast cancer and controls. These results suggest there could be an association of a single nucleotide polymorphism at position 276 of the C1qA component of complement with breast cancer metastasis to sites linked to hematogenous spread of disease. The C1qA polymorphism associated with decreased distant metastasis has also been correlated with an increased incidence of subcutaneous systemic lupus and C1q deficiencies, suggesting that an altered immune response may play a role in the observed association.
Similar content being viewed by others
References
Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y (2001) Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60:433–441
Baldwin WM III, Qian Z, Wasowska B, Sanfilippo F (1999) Complement causes allograft injury by cell activation rather than lysis. Transplantation 67:1498–1499
Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540–550
Boedefeld WM II, Bland KI, Heslin MJ (2003) Recent insights into angiogenesis, apoptosis, invasion, and metastasis in colorectal carcinoma. Ann Surg Oncol 10:839–851
Caragine TA, Okada N, Frey AB, Tomlinson S (2002) A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. Cancer Res 62:1110–1115
Carlini DB, Chen Y, Stephan W (2001) The relationship between third-codon position nucleotide content, codon bias, mRNA secondary structure and gene expression in the drosophilid alcohol dehydrogenase genes Adh and Adhr. Genetics 159:623–633
Conrad K (2000) Autoantibodies in cancer patients and in persons with a higher risk of cancer development. Elsevier, Amsterdam
Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc B 34:187–220
Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, Gejman PV (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12:205–216
Eccles SA (2001) Monoclonal antibodies targeting cancer: ‘magic bullets’ or just the trigger? Breast Cancer Res 3:86–90
Emmert S, Schneider TD, Khan SG, Kraemer KH (2001) The human XPG gene: gene architecture, alternative splicing and single nucleotide polymorphisms. Nucleic Acids Res 29:1443–1452
Erichsen HC, Chanock SJ (2004) SNPs in cancer research and treatment. Br J Cancer 90:747–751
Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M (2003) Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40:109–123
Gelderman KA, Tomlinson S, Ross GD, Gorter A (2004) Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25:158–164
Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900–3908
Hakulinen J, Meri S (1998) Complement-mediated killing of microtumors in vitro. Am J Pathol 153:845–855
Hansen MH, Ostenstad B, Sioud M (2001) Antigen-specific IgG antibodies in stage IV long-time survival breast cancer patients. Mol Med 7:230–239
Harjunpaa A, Junnikkala S, Meri S (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51:634–641
Jager D, Jager E, Knuth A (2001) Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 54:669–674
Jurianz K, Maslak S, Garcia-Schuler H, Fishelson Z, Kirschfink M (1999) Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology 42:209–218
Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Kauppi M, Pukkala E, Isomaki H (1997) Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 8:201–204
Khan SG, Muniz-Medina V, Shahlavi T, Baker CC, Inui H, Ueda T, Emmert S, Schneider TD, Kraemer KH (2002) The human XPC DNA repair gene: arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function. Nucleic Acids Res 30:3624–3631
Kishore U, Reid KB (2000) C1q: structure, function, and receptors. Immunopharmacology 49:159–170
Korb LC, Ahearn JM (1997) C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol 158:4525–4528
Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40:761–768
Modrek B, Resch A, Grasso C, Lee C (2001) Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 29:2850–2859
Onoe K, Iwabuchi K, Iwabuchi C, Tone S, Konishi J, Kawakami Y, Nishimura M (2002) Enhanced complement sensitivity of NK-T cells in murine thymus and spleen associated with presence of serum immunoglobulin. Immunobiology 206:377–391
Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448–456
Pardoll DM (1999) Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A 96:5340–5342
Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM (1985) Incidence of lung cancer in systemic sclerosis. J Rheumatol 12:1136–1139
Petry F, Loos M (2005) Common silent mutations in all types of hereditary complement C1q deficiencies. Immunogenetics 57:566–571
Posner JB (2003) Immunology of paraneoplastic syndromes: overview. Ann N Y Acad Sci 998:178–186
Racila E, Scheuermann RH, Picker LJ, Yefenof E, Tucker T, Chang W, Marches R, Street NE, Vitetta ES, Uhr JW (1995) Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J Exp Med 181:1539–1550
Racila DM, Sontheimer CJ, Sheffield A, Wisnieski JJ, Racila E, Sontheimer RD (2003) Homozygous single nucleotide polymorphism of the complement C1QA gene is associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus. Lupus 12:124–132
Ramsey-Goldman R, Mattai SA, Schilling E, Chiu YL, Alo CJ, Howe HL, Manzi S (1998) Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 46:217–222
Reid KB (1983) Proteins involved in the activation and control of the two pathways of human complement. Biochem Soc Trans 11:1–12
Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664
Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326:363–367
Tan EM (2001) Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 108:1411–1415
Tan EM, Shi FD (2003) Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin Exp Immunol 134:169–177
Tazawa H, Okada F, Kobayashi T, Tada M, Mori Y, Une Y, Sendo F, Kobayashi M, Hosokawa M (2003) Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. Am J Pathol 163:2221–2232
von Ahsen N, Oellerich M (2004) The intronic prothrombin 19911A>G polymorphism influences splicing efficiency and modulates effects of the 20210G>A polymorphism on mRNA amount and expression in a stable reporter gene assay system. Blood 103:586–593
Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058–1066
Webb KE, Martin JF, Cotton J, Erusalimsky JD, Humphries SE (2003) The 4830C>A polymorphism within intron 5 affects the pattern of alternative splicing occurring within exon 6 of the thrombopoietin gene. Exp Hematol 31:488–494
Zeng G, Li Y, El-Gamil M, Sidney J, Sette A, Wang RF, Rosenberg SA, Robbins PF (2002) Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 62:3630–3635
Zhu Y, Spitz MR, Amos CI, Lin J, Schabath MB, Wu X (2004) An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res 64:2251–2257
Acknowledgements
We gratefully acknowledge Melinda Andreski for patient consenting and collection and coding of blood specimens. We thank Carol Scott-Conner, Jean Arndt, Mark Karwal and Susan Roman for helping identify potential subjects. Input from all members of our research group, especially Drs. Brian Link and James Wooldridge, is recognized and appreciated.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported in part by National Institute of Health grant R21-CA90822, Friends You Can Count On! grant 1-87093-00, and the Woody and Louise White Cancer Research Fund.
Rights and permissions
About this article
Cite this article
Racila, E., Racila, D.M., Ritchie, J.M. et al. The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics 58, 1–8 (2006). https://doi.org/10.1007/s00251-005-0077-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00251-005-0077-y